Belly Button (Credit: Canva)
The belly button marks the exact spot where your umbilical cord was once attached—the vital connection that provided oxygen and nutrients in the womb. Once you started breathing, eating, and discharging waste on your own, this cord was no longer needed. What remains is a mark, a reminder of your months in your mother’s womb. However, it often gets ignored as you grow up. And there is nothing wrong with that. Your belly button does not require a special skincare routine, but neglecting its hygiene can lead to a buildup of bacteria, potentially causing a smelly discharge.
But generally, a discharge from your belly button is normal and colourless. According to experts, normal discharge is typically clear or light-coloured, has a slight odor (similar to sweat), and has no pain or redness around the navel.
Experts say that the most common funk you might encounter in your belly button is a bacterial or fungal infection. A study titled
A Jungle in There: Bacteria in Belly Buttons are Highly Diverse, but Predictable published in 2012 in PLOS One Journal states that once rarefied to four hundred reads per sample, bacterial communities from belly buttons proved to be at least as diverse as communities known from other skin studies (on average 67 bacterial phylotypes per belly button).
This occurs due to poor hygiene, excessive sweating, or trapped moisture. Other conditions include navel piercings, cysts, and skin conditions like eczema or psoriasis. People with diabetes are particularly susceptible to fungal infections such as candidiasis if their blood sugar isn't under control, according to a 2019 review in the Journal of Clinical Medicine.
Bacteria and fungi love the dark environment of your belly button. If your belly button is infected, you might notice some redness or swelling. The discharge might look like pus, making your belly button smell bad. If it's a yeast infection, your belly button might also itch.
Belly button or naval piercing, if infected, can lead to severe pain, discolouration, swelling, discharge and pus. It can also cause the skin to appear red, causing delayed or failed healing.
Other common signs include:
Chills or fever
Persistent pain or inflammation
Sensitivity or discomfort when moving
Swelling or tenderness to touch
Credits: Canva
Health authorities in the United Kingdom have released a fresh advisory on the use of antibiotics this winter. The UK Health Security Agency (UKHSA) reminded the public that these medicines are designed for specific types of illness and are not useful in every situation.
Antibiotics treat or prevent bacterial infections by killing the bacteria outright or limiting their ability to grow. This allows the body’s own immune defences to clear the remaining infection. What they cannot do is treat illnesses caused by viruses.
This includes common winter infections such as colds, flu, and COVID-19. In a post on X, the UKHSA said, “Antibiotics don't work for colds and flu. Pharmacists can guide you on managing your symptoms.”
The agency also urged people to keep a few basic points in mind when using antibiotics:
The reminder follows the release of the UKHSA’s English Surveillance Programme for Antimicrobial Utilisation and Resistance (ESPAUR) report, which shows that nearly 400 people in England each week are now diagnosed with infections that no longer respond well to antibiotics. These resistant infections are harder to treat and pose a greater risk of complications.
Experts believe that years of unnecessary or incorrect use of antibiotics have contributed to a decline in their effectiveness. This widespread overuse has also encouraged the rise of “superbugs”, a term used for bacteria that can withstand several commonly used antibiotics. Examples highlighted by the NHS include:
The NHS notes that these infections can be severe, difficult to control, and are becoming a growing cause of illness and death worldwide. The larger concern is that entirely new bacteria may emerge with resistance to every antibiotic currently available.
A cold usually develops slowly and tends to be milder. Typical signs include a runny or blocked nose, sneezing, a sore throat, mild cough, slight body ache, and low fever if any. Many people also feel pressure around the sinuses and a mild headache.
Flu sets in quickly and is generally more intense. People often experience a high fever, chills, deep muscle pain, marked fatigue, headache, dry cough, sore throat, and a sudden drop in energy. Some may also have nausea, loss of appetite, or chest discomfort.
Dr Alicia Demirjian, consultant epidemiologist and clinical lead for antimicrobial resistance and prescribing at the UKHSA, said, “Antibiotic resistance is one of the biggest threats facing modern medicine, but the good news is we can all do something about it.”
If a doctor has prescribed antibiotics, it is vital to take the medicine exactly as told, without skipping or delaying doses.
The NHS advises, “If you miss a dose, check the patient information leaflet to see what to do. If you are unsure, speak with a pharmacist or your GP. In many cases, you can take the missed tablet as soon as you remember and then continue the course as usual. If it is almost time for your next dose, leave out the missed one and return to your usual schedule.”
Credits: Gemini
A very common medical condition globally, sleep apnea is a disorder that interrupts breathing during sleep. Several factors can cause it, though the risk rises sharply with obesity because extra fat in the neck, known as pharyngeal fat, can narrow the airway. Health professionals usually advise lifestyle changes such as diet and exercise to ease symptoms, but if these steps do not help enough, weight-loss injections may be recommended.
Australia’s Therapeutic Goods Administration (TGA) has now approved the weight-loss drug Mounjaro as a treatment option for sleep apnea, a condition where a person repeatedly stops and starts breathing through the night. The TGA states that Mounjaro may be used for adults with moderate to severe obstructive sleep apnea who also meet the criteria for obesity with a body-mass index of 30 or more.
The United States Food and Drug Administration cleared the same drug for this purpose last year. This raises an important question. How could a medicine known mainly for weight management and type 2 diabetes support people struggling with sleep apnea?
Obstructive sleep apnea affects close to a billion people worldwide. It causes repeated pauses in breathing that disrupt sleep and reduce oxygen levels. Many people notice loud snoring, choking or gasping, and heavy daytime fatigue. The main forms are obstructive sleep apnea (OSA), caused by a blocked airway, and central sleep apnea (CSA), which occurs when the brain does not send the right signals to the breathing muscles. If ignored, it can raise the risk of high blood pressure, heart disease and stroke, according to the Mayo Clinic.
Obesity is one of the strongest contributors to obstructive sleep apnea. Roughly 80% of people diagnosed with the condition also live with obesity. The link runs in both directions. Extra fat around the neck can make the airway narrower and disturb breathing.
At the same time, sleep apnea can interfere with hunger and satiety hormones such as ghrelin and leptin, which can encourage overeating. Persistent tiredness makes it harder to stay active or maintain healthy habits, creating a cycle in which both problems feed into each other.
Mounjaro is the brand name for tirzepatide, also sold elsewhere under names like Zepbound. It works by activating receptors for two gut hormones known as GLP-1 and GIP. These hormones help control appetite, food intake and blood sugar. They are normally released when we eat, but tirzepatide mimics their action so people feel satisfied with smaller portions. Eating less overall can lead to gradual weight loss, which may improve sleep apnea symptoms in those whose condition is tied to obesity.
Although Mounjaro may be useful for some adults with sleep apnea, digestive side effects are fairly common. People may experience nausea, vomiting, diarrhoea, constipation or a drop in appetite. These issues often lessen as the body adjusts. Some users have also noted gallbladder-related concerns.
Even with these drawbacks, interest in Mounjaro as a sleep apnea therapy is growing because it offers a drug-based option for a condition long treated mainly with devices such as CPAP machines. Still, the medication is meant for people with obesity, and not everyone with sleep apnea falls into that category.
It is always best to speak with a healthcare provider before beginning or stopping any prescribed treatment.
Credits: Canva
A three-year-old boy from California has stunned doctors with his rapid progress after receiving a world-first gene therapy for Hunter syndrome, a rare inherited condition that causes progressive damage to the body and brain. The treatment was carried out at the Royal Manchester Children’s Hospital and offers new hope for families who have long lived with the devastating effects of the disease.
Hunter syndrome is caused by a faulty gene that prevents patients from producing an enzyme needed to clear certain molecules from cells. Children appear healthy at birth but start showing symptoms around age two. The condition affects the heart, liver, bones and brain and is often described as a form of childhood dementia. Most severely affected patients rarely live beyond their teenage years.
Before treatment, Oliver Chu could not produce the crucial enzyme, reports BBC. Conventional therapy required weekly infusions that only slowed physical decline and could not protect the brain. Doctors in Manchester decided to attempt a one-time gene therapy, something never tried before for this condition.
Stem cells were collected from Oliver’s blood in December 2024 and sent to a specialist laboratory at Great Ormond Street Hospital in London. Scientists inserted a working copy of the missing gene into a harmless virus. The virus delivered the corrected gene into Oliver’s stem cells, allowing them to produce the missing enzyme once infused back into his body. Researchers also modified the gene to help the enzyme travel more easily into the brain, a major challenge in previous treatments.
In February 2025, Oliver returned to Manchester for the infusion. His corrected stem cells, about 125 million of them, arrived frozen in a cryopreservation tank. After several safety checks, nurses slowly injected two doses into a catheter in his chest. The entire process took minutes, but the hope behind it was enormous. Once the infusion was complete, Oliver and his mother returned to California to wait for results.
By May, the effects were becoming clear. Oliver’s speech had improved, his mobility had increased, and his parents described him as “brighter” and “healthier.” Most significantly, he no longer needed the expensive weekly enzyme infusions. His body had begun producing the enzyme on its own.
His older brother Skyler, who also has Hunter syndrome, accompanied the family to Manchester during this follow-up visit. Their parents now hope Skyler may also qualify for the therapy one day.
By late August, nine months after treatment, doctors confirmed that Oliver was producing far above normal levels of the missing enzyme. He was gaining new words, moving more easily and showing continued cognitive progress. Professor Simon Jones, who co-leads the trial, praised Oliver’s development but noted that researchers still need long-term data.
Five boys from the United States, Europe and Australia are enrolled in the ongoing trial. No UK patients qualified because most were diagnosed too late. Participants will be monitored for at least two years to assess effectiveness and safety.
The gene therapy almost never reached patients. Researchers at the University of Manchester had spent over 15 years developing it but nearly lost funding when their biotech partner withdrew. A last-minute contribution of 2.5 million pounds from the medical charity LifeArc saved the trial and allowed children like Oliver to join.
His parents say they are “eternally grateful” and feel his life has been “reset.” For them, the treatment represents not just medical progress but a future filled with possibilities.
© 2024 Bennett, Coleman & Company Limited